Premium
Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy
Author(s) -
Karol Seth E.,
CoustanSmith Elaine,
Cao Xueyuan,
Shurtleff Sheila A.,
Raimondi Susana C.,
Choi John K.,
Ribeiro Raul C.,
Dahl Gary V,
Bowman William Paul,
Taub Jeffrey W.,
Degar Barbara,
Leung Wing,
Downing James R.,
Pui ChingHon,
Rubnitz Jeffrey E.,
Campana Dario,
Inaba Hiroto
Publication year - 2015
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13107
Subject(s) - medicine , minimal residual disease , myeloid leukaemia , oncology , complete remission , disease , cohort , myeloid , induction chemotherapy , pediatrics , overall survival , chemotherapy , leukemia
Summary Minimal residual disease ( MRD ) is a strong prognostic factor in children and adolescents with acute myeloid leukaemia ( AML ) but nearly one‐quarter of patients who achieve MRD ‐negative status still relapse. The adverse prognostic factors among MRD ‐negative patients remain unknown. We analysed the AML 02 study cohort to identify demographic and genetic prognostic factors. Among the presenting features, certain 11q23 abnormalities, such as t(6;11) and t(10;11), acute megakaryoblastic leukaemia without the t(1;22), and age ≥10 years were associated with inferior outcome in patients who had MRD ‐negative status after either remission induction I or II . By contrast, those with rearrangement of CBF genes had superior outcome. Our study identifies patient populations for whom close post‐remission MRD monitoring to detect and treat emerging relapse and adjustment in treatment intensity might be indicated.